$1.06
Cytosorbents
Performance
Dividends
9.28%
1W
1M
YTD
1Y
3Y
13/36
Growth Score
10/36
Dividend Score
Valuation
PE Ratio
-4.06
PS Ratio
2.4
RSI
-
0
PEG Ratio
0
3
PRG Ratio
0.16
PDG Ratio
0
Growth
024%0-2%010%124%
13%27%56%28%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
106.17%
3
Gross Margin
96.22%
2
Current Ratio
2.61
Return on Assets
-31.19%
Return on Equity
-114.39%
Return on inv. Capital
-33.87%
Institutional Holder
16.850.964018.239.724
61170
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 35.59M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -20.72M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 25.13M
2018
2019
2020
2021
2022
2023
2024
6
Events
CTSO
Cytosorbents
in 467 days
after market close
Earnings per Share is expected with - and revenue with - .
CTSO
Cytosorbents
in 382 days
after market close
Earnings per Share is expected with - and revenue with - .
CTSO
Cytosorbents
in 285 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Devices
IPO Date
08.08.2006
MaketCap
66.37M
Country
US
CEO
Phillip P. Chan
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Updated 12.07.2025